Abstract
Adenosine (ADO) is an endogenous inhibitory neuromodulator that increases nociceptive thresholds in response to tissue trauma and inflammation. Adenosine kinase (AK) is a key intracellular enzyme regulating intra- and extracellular concentrations of ADO. AK inhibition selectively amplifies extracellular ADO levels at cell and tissue sites where accelerated release of ADO occurs. AK inhibitors have been shown to provide effective antinociceptive, antiinflammatory and anticonvulsant activity in animal models, thus suggesting their potential therapeutic utility for pain, inflammation, epilepsy and possibly other central and peripheral nervous system diseases associated with cellular trauma and inflammation. This beneficial outcome may potentially lack nonspecific effects associated with the systemic administration of ADO receptor agonists. Until recently all of the reported AK inhibitors contained adenosine-like structural motif. The present review will discuss design, synthesis and analgesic and antiinflammatory properties of the novel nonnucleoside AK inhibitors that do not have close structural resemblance with the natural substrate ADO. Two classes of the nonnucleoside AK inhibitors are built on pyridopyrimidine and alkynylpyrimidine cores.
Keywords: adenosine kinase inhibitor, adenosine, pyridopyrimidines, alkynylpyrimidines, analgesia, Inflammation
Current Pharmaceutical Design
Title: Nonnucleoside Inhibitors of Adenosine Kinase
Volume: 10 Issue: 10
Author(s): Arthur Gomtsyan and Chih-Hung Lee
Affiliation:
Keywords: adenosine kinase inhibitor, adenosine, pyridopyrimidines, alkynylpyrimidines, analgesia, Inflammation
Abstract: Adenosine (ADO) is an endogenous inhibitory neuromodulator that increases nociceptive thresholds in response to tissue trauma and inflammation. Adenosine kinase (AK) is a key intracellular enzyme regulating intra- and extracellular concentrations of ADO. AK inhibition selectively amplifies extracellular ADO levels at cell and tissue sites where accelerated release of ADO occurs. AK inhibitors have been shown to provide effective antinociceptive, antiinflammatory and anticonvulsant activity in animal models, thus suggesting their potential therapeutic utility for pain, inflammation, epilepsy and possibly other central and peripheral nervous system diseases associated with cellular trauma and inflammation. This beneficial outcome may potentially lack nonspecific effects associated with the systemic administration of ADO receptor agonists. Until recently all of the reported AK inhibitors contained adenosine-like structural motif. The present review will discuss design, synthesis and analgesic and antiinflammatory properties of the novel nonnucleoside AK inhibitors that do not have close structural resemblance with the natural substrate ADO. Two classes of the nonnucleoside AK inhibitors are built on pyridopyrimidine and alkynylpyrimidine cores.
Export Options
About this article
Cite this article as:
Gomtsyan Arthur and Lee Chih-Hung, Nonnucleoside Inhibitors of Adenosine Kinase, Current Pharmaceutical Design 2004; 10 (10) . https://dx.doi.org/10.2174/1381612043452703
DOI https://dx.doi.org/10.2174/1381612043452703 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetics of Serotonin Receptors and Depression: State of the Art
Current Drug Targets Clozapine Safety, 40 Years Later
Current Drug Safety Mitochondrial Encephalomyopathies in Children. Part I: Conventional MR Imaging Findings
Current Medical Imaging The Role of Innate Immune System Receptors in Epilepsy Research
CNS & Neurological Disorders - Drug Targets Ultrasound-promoted Organic Synthesis - A Recent Update
Current Organic Chemistry The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Common Issues Among Asthma, Epilepsy, and Schizophrenia: From Inflammation to Ca<sup>2+</sup>/cAMP Signalling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
Current Neuropharmacology Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Long-Term Effects of Hypoxia-Reoxygenation on Thioredoxins in Rat Central Nervous System
Current Pharmaceutical Design A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders
Current Topics in Medicinal Chemistry Serotonin Control of Dopaminergic Neurotransmission: Focus on 5-HT2 Receptors
Current Neuropharmacology Transcranial Direct Current Stimulation - An Adjuvant Tool for the Treatment of Neuropsychiatric Diseases?
Current Psychiatry Reviews Increased Epileptiform EEG Activity and Decreased Seizure Threshold in Arctic APP Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry